The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Autor(es)

Medeiros, Mariana ^[1] ; Candido, Marina Ferreira ^[1] ; Valera, Elvis Terci ^[2] ; Brassesco, Maria Sol ^[3]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Cell Biol, Ribeirao Preto, SP - Brazil

^[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Ribeirao Preto, SP - Brazil

^[3] Univ Sao Paulo, FFCLRP USP, Fac Philosophy Sci & Letters Ribeirao Preto, Dept Biol, Av Bandeirantes 3900, BR-14040901 Ribeirao Preto, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: CELLULAR AND MOLECULAR LIFE SCIENCES; v. 78, n. 17-18 JUL 2021.
• Citações Web of Science: 0

Resumo

Despite advances in the understanding of the molecular mechanisms underlying the basic biology and pathogenesis of pediatric central nervous system (CNS) malignancies, patients still have an extremely unfavorable prognosis. Over the years, a plethora of natural and synthetic compounds has emerged for the pharmacologic intervention of the NF-kB pathway, one of the most frequently dysregulated signaling cascades in human cancer with key roles in cell growth, survival, and therapy resistance. Here, we provide a review about the state-of-the-art concerning the dysregulation of this hub transcription factor in the most prevalent pediatric CNS tumors: glioma, medulloblastoma, and ependymoma. Moreover, we compile the available literature on the anti-proliferative effects of varied NF-kB inhibitors acting alone or in combination with other therapies in vitro, in vivo, and clinical trials. As the wealth of basic research data continues to accumulate, recognizing NF-kB as a therapeutic target may provide important insights to treat these diseases, hopefully contributing to increase cure rates and lower side effects related to therapy. (AU)

• Processo FAPESP: 10/16652-9 - Inibição do NF-kB em glioblastoma: efeitos in vitro e in vivo do DHMEQ na quimioresistência, invasão e proliferação tumoral
• Beneficiário: María Sol Brassesco Annichini
• Modalidade de apoio: Bolsas no Brasil - Jovens Pesquisadores
• Processo FAPESP: 10/50635-4 - Inibição do NF-Kb em glioblastoma: efeitos in vitro e in vivo do DHMEQ na quimioresistência, invasão e proliferação tumoral
• Beneficiário: María Sol Brassesco Annichini
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores